 ATLANTA--BUSINESS WIRE--Virios Therapeutics, Inc. Nasdaq: VIRI, a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that clinical data from its Phase 2a trial of IMC-1 in fibromyalgia FM is featured in a poster presentation poster POS0017 at the annual EULAR European Congress of Rheumatology, a renowned forum for interaction between medical doctors, sci 